[NEWSM] PAmid global Big Pharma continues to recover from the impact of the COVID-19 endemic, obesity treatments are creating a new landscape.
According to second-quarter reports from major global Big Pharma companies compiled by Newsmp, most of them expanded their growth compared to the first quarter.
Notably, Pfizer, which saw a nearly 20% decline in the first quarter due to a sharp drop in COVID-19 vaccine and treatment sales, rebounded with a 2.1% revenue growth in the second quarter.
Moderna, which Q1 revenue plummeted by more than 90% due to declining vaccine sales, continued to face negative growth in Q2, but the decline was significantly reduced to around 30%.
Roche also marked a turnaround, with 6.9% sales growth in Q2 after 6.0% decline in Q1, balancing its half-year results. Biogen, which experienced a 7.0% decline in revenue in Q1, also grew 0.4% in Q2.
Lilly and Novo Nordisk, enjoying a boom with obesity treatments, expanded their growth further in Q2.
Lilly, which saw a 26.0% revenue growth in Q1, expanded its growth to 36.0% by 10.0 percentage points in Q2, while Novo Nordisk's sales growth rate rose from 22.5% to 25.3% during the same period.
Amgen, which significantly expanded its size through mergers, posted revenue growth of more than 20% in Q2.
GSK and AstraZeneca also continued to grow in double digits. GSK's sales growth rate increased from 10.0% to 11.6%, while AstraZeneca's revenue growth slightly decreased from 16.5% to 13.3% but maintained double-digit growth.
Additionally, BMS grew 8.7% in Q2, up from 4.6% in Q1; Sanofi grew 7.8% up from 2.4%; Johnson & Johnson grew 4.3% up from 2.3%; and AbbVie grew 4.3% up from 0.7%.
On the other hand, MSD's growth rate slightly decreased from 8.9% in Q1 to 7.2% in Q2, Organon, which grew 5.5% in Q1, saw a slight decline. The growth rates of Novartis and Gilead remained relatively stable at 9.4% and 5.4%, similar to Q1 (9.5% and 5.3%, respectively).
